ClinicalTrials.gg

Program

idursulfase beta

Also written as “Hunterase”.

Its studies are mostly in Mucopolysaccharidosis II · Sudden Infant Death, led by GC Biopharma.

Furthest: phase 3, since Jul 16, 20123 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GC Biopharma30 open or runningphase 3since Jul 16, 2012Jul 16, 2012none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 16, 2012First study: phase 3 study in Mucopolysaccharidosis IIFirst studyNCT01645189 · 6 enrolled · Korea, Republic of
  2. Jan 17, 2016Phase 2 study in Mucopolysaccharidosis IINCT02663024 · 20 enrolled
  3. Nov 17, 2025Phase 3 study in Sudden Infant DeathNCT07344376 · 30 enrolled · South Korea

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07344376Sudden Infant Death · South Korea3CompletedDec 30, 202230
NCT02663024Mucopolysaccharidosis II2UNKNOWNDec 201920
NCT01645189Mucopolysaccharidosis II · Korea, Republic of3CompletedSep 20136

How it is read

Names in the registry

  • “Hunterase”, 2 entries
  • “idursulfase beta”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.